PharmaShots | Incisive News in 3 Shots

Subscribe Now

Aurinia

Aurinia Published P-III Extension Study (AURORA 2) Results of Lupkynis (voclosporin) for Lupus Nephritis in Arthritis & Rheumatology

Aurinia Published P-III Extension Study (AURORA 2) Results of Lupkynis (voclosporin) for Lupus Nephritis in Arthritis & Rheumatolo...

July 20, 2023

Dr. Volker Knappertz, EVP R&D, Aurinia Shares Insights on LUPKYNIS MAA from EMA

Dr. Volker Knappertz, EVP R&D, Aurinia Shares Insights on LUPKYNIS MAA from EMA

December 7, 2022

Aurinia’s Lupkynis (voclosporin) Receives EC’s Approval for the Treatment of Lupus Nephritis

Aurinia’s Lupkynis (voclosporin) Receives EC’s Approval for the Treatment of Lupus Nephritis

September 20, 2022

PharmaShots Interview: Aurinia's Neil Solomons Shares Insights on the Lupkynis

PharmaShots Interview: Aurinia's Neil Solomons Shares Insights on the Lupkynis

June 1, 2021

PharmaShots Weekly Snapshots (May 17 - 21, 2021)

PharmaShots Weekly Snapshots (May 17 - 21, 2021)

May 21, 2021

PharmaShots Weekly Snapshots (May 10 - 14, 2021)

PharmaShots Weekly Snapshots (May 10 - 14, 2021)

May 14, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us